Immunotherapy, such as PD-L1 blockade therapy, has contributed to the curative effectiveness in many advanced malignancies, including advanced BC, while the heterogeneity of the response rate still limits its clinical application (Carosella et al., 2015; Oh et al., 2020). This evidence concerns the gene CD274 and breast cancer.